Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Implementation of the system to provide faster, seamless and hassle-free healthcare solutions
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
National Institute of Animal Biotechnology, Hyderabad can now conduct quality checks and consequent lot release of Covid-19 vaccines
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
CDSCO to fast-track trials and approval for COVID19 vaccine
AstraZeneca, Sinopharm and Moderna were part of the study
Five seats reserved for Wards of COVID warriors in central MBBS admission
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
Subscribe To Our Newsletter & Stay Updated
